Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 81Carcinoma, Non-Small-Cell Lung 41Colonic Neoplasms 40Lung Neoplasms 39Leukemia 36Rectal Neoplasms 34Lymphoma 34Colorectal Neoplasms 33Prostatic Neoplasms 24Multiple Myeloma 23Lymphoma, Follicular 22Leukemia, Myeloid, Acute 19Ovarian Neoplasms 18Lymphoma, Non-Hodgkin 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Melanoma 16Head and Neck Neoplasms 15Urinary Bladder Neoplasms 14Neoplasms, Plasma Cell 14Lymphoma, Large-Cell, Immunoblastic 14Burkitt Lymphoma 14Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Leukemia, Myelomonocytic, Acute 12Leukemia, Monocytic, Acute 12Leukemia, Megakaryoblastic, Acute 12Leukemia, Erythroblastic, Acute 12

Interventions

pegvisomant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NIH × Fibrous Dysplasia, Polyostotic × Clear all
NCT00017927 2008-03-04

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
10 enrolled

Acromegaly, Adenoma, Fibrous Dysplasia, Polyostotic, Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡